Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21459915 | 1.00 | IDH1 (0.41) | IDH1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL13575346 | 0.78 | IDH1 (0.44) | IDH1ALDH1A1SMN1; SMN2LMNANPC1 | |
| SCHEMBL13575341 | 0.72 | KDM4E (0.50) | IDH1LMNAPADI4ESR1KDM4E | |
| SCHEMBL1423375 | 0.70 | — | — | |
| SCHEMBL3719326 | 0.69 | — | — | |
| SCHEMBL9261222 | 0.69 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDTSHRHSD17B10 | |
| SCHEMBL5384397 | 0.66 | RELA (0.58) | SMN1; SMN2NPC1RAB9ACYP2C9CYP2C19 | |
| SCHEMBL5384402 | 0.66 | RELA (0.58) | SMN1; SMN2NPC1RAB9ACYP2C9CYP2C19 | |
| SCHEMBL9197132 | 0.65 | BAZ2B (0.47) | ALDH1A1LMNACYP1A2 | |
| SCHEMBL10981021 | 0.64 | APP (0.54) | ALDH1A1SMN1; SMN2LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | MORPHIC THERAPEUTIC, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2022-10-27 | — | — | US | disclosed |
| EP-4045039-A1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | MORPHIC THERAPEUTIC, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | MORPHIC THERAPEUTIC, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| WO-2021076902-A1 | INHIBITING HUMAN INTEGRIN α 4 β 7 | MORPHIC THERAPEUTIC, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| EP-3773573-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | Morphic Therapeutic, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | IDH1 4743/4885ALDH1A1 1361/4885SMN1; SMN2 2490/4885 |
| US-11370773-B1 | Inhibiting human integrin (alpha-4) (beta-7) | ITGB7, ITGB4, ITGA4 | IDH1 4401/4885ALDH1A1 1165/4885SMN1; SMN2 2204/4885 |
| US-20240174632-A1 | INHIBITING HUMAN INTEGRIN (ALPHA-4) (BETA-7) | ITGB7, ITGB4, ITGA4 | IDH1 4401/4885ALDH1A1 1165/4885SMN1; SMN2 2204/4885 |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | IDH1 4743/4885ALDH1A1 1361/4885SMN1; SMN2 2490/4885 |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | IDH1 4743/4885ALDH1A1 1361/4885SMN1; SMN2 2490/4885 |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | IDH1 4687/4885ALDH1A1 1457/4885SMN1; SMN2 2406/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | IDH1 4743/4885ALDH1A1 1361/4885SMN1; SMN2 2490/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | IDH1 4558/4885ALDH1A1 1396/4885SMN1; SMN2 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.